The firm is representing Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, in its $50 million private placement.
The financing is led by new investors Octagon Capital and Great Point Partners, LLC, with participation from new and existing healthcare institutional investors including Logos Capital, Nantahala Capital, SilverArc Capital, Velan Capital, Vivo Capital and Walleye Capital.
Sheppard Mullin previously advised Unicycive in its $130 million private placement in March 2023.
The deal was led by partner and co-leader of the firm’s Life Sciences team Jeff Fessler and special counsel Greg Carney.
Click here to read the press release.
